ArticleLung cancer (Amsterdam, Netherlands)2012
Natural growth and disease progression of non-small cell lung cancer evaluated with 18F-fluorodeoxyglucose PET/CT.
Article in Lung cancer (Amsterdam, Netherlands), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review.Thorax · 2022Pooled it
- Necessity of organized low-dose computed tomography screening for lung cancer: From epidemiologic comparisons between China and the Western nations.Oncotarget · 2017Pooled it
- A Pilot Study on Qualitative Metabolomics to Characterize Lewis Lung Carcinoma in Mice.Life (Basel, Switzerland) · 2025Article
- International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.JAMA network open · 2024Article
- Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient Outcomes.Clinical lung cancer · 2024Article
- Strategies for engineering oncolytic viruses to enhance cancer immunotherapy.Frontiers in pharmacology · 2024Review
- Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab.CPT: pharmacometrics & systems pharmacology · 2021Article
- Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials.Breathe (Sheffield, England) · 2020Review
- The Impact of Delays to Definitive Surgical Care on Survival in Colorectal Cancer Patients.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Article
- Prognostic Impact of Tumor Doubling Time in Patients with Metachronous Lung Cancer.World journal of surgery · 2019Article
- Article
- Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients.Thorax · 2018Article
- Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization.Translational lung cancer research · 2017Review
- Article
- Prediction of Treatment Response for Combined Chemo- and Radiation Therapy for Non-Small Cell Lung Cancer Patients Using a Bio-Mathematical Model.Scientific reports · 2017Article
- Observational
- Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer: cohort study.BMJ (Clinical research ed.) · 2015Article
- A differentiated approach to referrals from general practice to support early cancer diagnosis - the Danish three-legged strategy.British journal of cancer · 2015Article
- Article
- Pulmonary ventilation imaging based on 4-dimensional computed tomography: comparison with pulmonary function tests and SPECT ventilation images.International journal of radiation oncology, biology, physics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThe aims of this study were to: (1) estimate the volumetric and metabolic growth rate of non-small cell lung cancer (NSCLC), (2) evaluate disease progression prior to treatment, and (3) explore the effects of tumor growth rate and time to treatment (TTT) on survival outcome.
methodsPatients with inoperable stages I-III NSCLC with serial pre-treatment PET/CT scans were eligible for this study. PET-derived metabolic tumor volumes (PET-MTV) and CT-derived gross tumor volumes (CT-GTV) were contoured using PET/CT information. Normalized standardized uptake values (NSUV) in tumors including the NSUVmean and NSUVmax were measured. Tumor growth rates expressed as doubling time (DT) were estimated using an exponential model. Pre-treatment disease progression defined as the development of any new site of disease on PET/CT and change in TNM stage (AJCC 7th ed.) were recorded. Growth rate and tumor progression were analyzed with respect to overall (OS) and progression free survival (PFS).
resultsThirty-four patients with a median inter-scan interval (ISI) of 43 days and TTT of 48 days were analyzed. Tumor volumes showed remarkable inter-scan growth while NSUV did not increase significantly. The DT for PET-MTV, CT-GTV, NSUVmean and NSUVmax were 124, 139, 597, and 333 days, respectively. Pre-treatment disease progression occurred in 20.6% patients with longer ISI being a significant risk factor (OR=1.027, p=0.02). The optimal threshold ISI to predict progression was 58 days (4.8% vs. 46.2%, p=0.007). Neither tumor growth rates nor TTT were significantly correlated to OS or PFS.
conclusionsNSCLC displays rapid tumor volume growth whereas NSUVmean and NSUVmax are relatively stable over the same time period. Longer delays before initiation of treatment are associated with higher risk of pre-treatment disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.